MD Andrson Cancer Center
Welcome,         Profile    Billing    Logout  
 11 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pemmaraju, Naveen
NCT04109482: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Hourglass Oct 2021 - Dec 2021 : Data from trial for AML/BPDCN/MDS
Terminated
1/2
3
US
MB-102, CD123 CAR-T, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
Mustang Bio
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
05/23
05/23
CYNK001AML01, NCT04310592: Natural Killer Cell (CYNK-001) Infusions in Adults With AML

Recruiting
1
94
US
CYNK-001
Celularity Incorporated
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
06/24
12/24
NCT06613217: Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

Not yet recruiting
1
35
NA
zelenirstat, PCLX-001
Pacylex Pharmaceuticals, Ozmosis Research Inc., United States Department of Defense
Relapsed Adult AML
03/26
09/26

Download Options